Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model. Issue 7 (11th February 2020)

• Record Type: Journal Article
• Authors: Jo, Su Kyoung; Ahn, Bo-Eun; Choi, Eun Hye; Kang, Ji Eun; An, Hyonggin; Oh, Myoung-don; Rhie, Gi-eun
• Is Part Of: Vaccine. Volume 38:Issue 7(2020)
• Page Start: 1586
• Page End: 1588
• Publication Date: 2020-02-11
• Subjects: Anthrax vaccine -- Passive immunization -- Toxin neutralization assay -- Survival rate; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.12.048
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to A/J mice and the mice were subsequently challenged with 100 × LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.